Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Klin Med (Mosk) ; 90(4): 59-62, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22896984

RESUMO

The study aimed at estimating the pharmacotherapeutic efficacy of medications possessed of antiviral activity, such as ribavirin, cycloferon solution and tablets, in 410 patients with Crimean hemorrhagic fever: The early beginning of therapy (days 1-4 after the onset of the disease) with these drugs reduced the number of severe cases and manifestations of hemorrhagic syndrome. The duration of the disease decreased, the occurrence of intoxication syndrome reduced to a minimum, hemorrhagic rash rapidly disappeared, and the frequency of complications decreased. Adverse events were documented in 5.2% of the patients (n = 15); most of them developed on day 2 after using the drugs, their duration did not exceed 2.2 days. There were no cases of drug withdrawal.


Assuntos
Acridinas/administração & dosagem , Antivirais/administração & dosagem , Febre Hemorrágica da Crimeia/tratamento farmacológico , Indutores de Interferon/administração & dosagem , Ribavirina/administração & dosagem , Acridinas/efeitos adversos , Antivirais/efeitos adversos , Febre Hemorrágica da Crimeia/fisiopatologia , Humanos , Indutores de Interferon/efeitos adversos , Pessoa de Meia-Idade , Ribavirina/efeitos adversos , Resultado do Tratamento
2.
Eksp Klin Farmakol ; 75(1): 23-6, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22442959

RESUMO

Dose-dependent interferonogenic activity and pharmacokinetics of cycloferon--a low-molecular inductor of interferon--have been studied in a group of 35 healthy volunteers. It is established that cycloferon induces the production of early alpha-IFN within 24 h from the moment of drug introduction. In a dose of 500 mg, the drug induces production of gamma-IFN by leukocytes in vitro within 24 h from the moment of introduction, with retention of the titer for 48 h. This proves the need for differentiated approach to a choice of the dose of cycloferon, depending on diseases in which complex treatment involving interferon inductors is required. After the introduction of cycloferon (500 mg) in healthy volunteers, the peak of drug concentration in the blood is observed in 40 min, with the subsequent considerable decrease within 2 h. Variation of the cycloferon concentration in the blood correlates with its content in urine, which is evidence for the drug elimination from organism through kidneys.


Assuntos
Acridinas/administração & dosagem , Acridinas/farmacocinética , Indutores de Interferon/administração & dosagem , Indutores de Interferon/farmacocinética , Interferon-alfa/sangue , Interferon gama/sangue , Adulto , Feminino , Humanos , Leucócitos/metabolismo , Masculino
3.
Antibiot Khimioter ; 57(7-8): 12-22, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23350190

RESUMO

Search for drugs efficient in prophylaxis and treatment of dangerous infections (especially arboviral ones) is rather actual, since no specific therapy is available. Many-year investigations of interferon inductors showed that they had immunomodulating, antiviral and antiinflammatory effects and were low toxic. The present study demonstrated that the protective effect was the following: Venezuelan equine encephalitis (VEE)--cycloferon > amixin = ridostin, Rift Valley fever (RVF)--cycloferon > amixin > ridostin, predator pox (PP)--cycloferon > amixin = ridostin, that was obvious that cycloferon was the most active agent in the treatment of VEE, RVF and PP, thus making it possible to acknowledge its priority in prophylaxis and therapy of dangerous viral infections (DVI). Ribavirin in combination with cycloferon solution or cycloferon tablets provided shorter periods of the fever, minimized the intoxication syndrome, promoted earlier resolution of hemorrhagic eruption and lowered the frequency of complications, which was in favour of the disease prognosis.


Assuntos
Acridinas/uso terapêutico , Antivirais/uso terapêutico , Encefalomielite Equina Venezuelana/tratamento farmacológico , Febre Hemorrágica da Crimeia/tratamento farmacológico , Indutores de Interferon/uso terapêutico , Febre do Vale de Rift/tratamento farmacológico , Acridinas/farmacologia , Adolescente , Adulto , Idoso , Animais , Antivirais/farmacologia , Dengue/tratamento farmacológico , Dengue/etiologia , Encefalomielite Equina Venezuelana/etiologia , Feminino , Humanos , Indutores de Interferon/farmacologia , Ixodes/virologia , Masculino , Camundongos , Pessoa de Meia-Idade , RNA de Cadeia Dupla/farmacologia , RNA de Cadeia Dupla/uso terapêutico , RNA Fúngico/farmacologia , RNA Fúngico/uso terapêutico , Ribavirina/uso terapêutico , Febre do Vale de Rift/etiologia , Febre do Vale de Rift/transmissão , Tilorona/uso terapêutico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA